Optimal donor for African Americans with hematologic malignancy: HLA-haploidentical relative or umbilical cord blood transplant.

[1]  C. Lamers,et al.  CD4+ T-cell alloreactivity after haploidentical hematopoietic stem cell transplantation , 2020, Haematologica.

[2]  S. Devlin,et al.  Racial disparities in access to HLA-matched unrelated donor transplants: a prospective 1312-patient analysis. , 2019, Blood advances.

[3]  N. Geller,et al.  Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduce , 2019, The Lancet. Haematology.

[4]  P. Chiusolo,et al.  Unrelated cord blood transplantation and post-transplant cyclophosphamide , 2018, Haematologica.

[5]  M. Solh,et al.  Superior Survival of Black Versus White Patients Following Post-Transplant Cyclophosphamide-Based Haploidentical Transplantation for Adults with Hematologic Malignancy. , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[6]  M. Perales,et al.  Prospective Evaluation of Unrelated Donor Cord Blood and Haploidentical Donor Access Reveals Graft Availability Varies by Patient Ancestry: Practical Implications for Donor Selection. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  J. Falkenburg,et al.  CD4+ T-cell alloreactivity toward mismatched HLA class II alleles early after double umbilical cord blood transplantation. , 2016, Blood.

[8]  M. Aljurf,et al.  GVHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes , 2016, Bone Marrow Transplantation.

[9]  M. Norkin,et al.  Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[10]  M. Maiers,et al.  Biology of Blood and Marrow Transplantation , 2022 .

[11]  Loren Gragert,et al.  HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. , 2014, The New England journal of medicine.

[12]  J. Klein,et al.  Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy. , 2014, Blood.

[13]  J. Wingard,et al.  Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. , 2011, Blood.

[14]  J. Wagner,et al.  Reduced-intensity conditioning transplantation in acute leukemia: the effect of source of unrelated donor stem cells on outcomes. , 2010, Blood.

[15]  J. Klein,et al.  Relationship of race/ethnicity and survival after single umbilical cord blood transplantation for adults and children with leukemia and myelodysplastic syndromes. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[16]  J. Wagner,et al.  Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. , 2010, The Lancet. Oncology.

[17]  J. Klein,et al.  Race and socioeconomic status influence outcomes of unrelated donor hematopoietic cell transplantation. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[18]  B. Sandmaier,et al.  Defining the intensity of conditioning regimens: working definitions. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[19]  W. Stock,et al.  Paucity of HLA-identical unrelated donors for African-Americans with hematologic malignancies: the need for new donor options. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[20]  Xu Zhang,et al.  A SAS macro for estimation of direct adjusted survival curves based on a stratified Cox regression model , 2007, Comput. Methods Programs Biomed..

[21]  J P Klein,et al.  Testing for centre effects in multi-centre survival studies: a Monte Carlo comparison of fixed and random effects tests. , 1999, Statistics in medicine.

[22]  D. Lin,et al.  Non-parametric inference for cumulative incidence functions in competing risks studies. , 1997, Statistics in medicine.

[23]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[24]  K. Sullivan,et al.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. , 1980, The American journal of medicine.

[25]  B. Wood,et al.  Cord-Blood Transplantation in Patients with Minimal Residual Disease. , 2016, The New England journal of medicine.

[26]  P. Veys,et al.  Impact of thymoglobulin prior to pediatric unrelated umbilical cord blood transplantation on immune reconstitution and clinical outcome. , 2014, Blood.

[27]  Mei-Jie Zhang,et al.  SAS macros for estimation of direct adjusted cumulative incidence curves under proportional subdistribution hazards models , 2011, Comput. Methods Programs Biomed..

[28]  D.,et al.  Regression Models and Life-Tables , 2022 .